EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan

Cheng-Yi Lee, Hung-Wei Kuo, Yu-Lun Liu, Jen-Hsiang Chuang, Jih-Haw Chou

Emerging Infectious Diseases · 2024-03 · 30 (3)

DOI: 10.3201/eid3003.230893 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Emerging Infectious Diseases, 2024-03. Verfasst von Cheng-Yi Lee und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Taiwan provided several COVID-19 vaccine platforms: mRNA (BNT162b2, mRNA-1273), adenoviral vector-based (AZD1222), and protein subunit (MVC-COV1901). After Taiwan shifted from its zero-COVID strategy in April 2022, population-based evaluation of vaccine effectiveness (VE) became possible. We conducted an observational cohort study of 21,416,151 persons to examine VE against SARS-CoV-2 infection, moderate and severe illness, and death during March 22, 2021-September 30, 2022. After adjusting for age and sex, we found that persons who completed 3 vaccine doses (2 primary, 1 booster) or received MVC-COV1901 as the primary series had the lowest hospitalization incidence (0.04-0.20 cases/100,000 person-days). We also found 95.8% VE against hospitalization for 3 doses of BNT162b2, 91.0% for MVC-COV1901, 81.8% for mRNA-1273, and 65.7% for AZD1222, which had the lowest overall VE. Our findings indicated that protein subunit vaccines provide similar protection against SARS-CoV-2---associated hospitalization as mRNA vaccines and can inform mix-and-match vaccine selection in other countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Humans2019-nCoV Vaccine mRNA-1273BNT162 VaccineChAdOx1 nCoV-19Cohort StudiesCOVID-19 VaccinesSARS-CoV-2TaiwanVaccine EfficacyMaleFemale

Stichwörter der Autor:innen

AZD1222BNT162b2COVID-19MVC-COV1901SARSSARS-CoV-2Taiwancoronaviruscoronavirus diseasemRNA-1273mix-and-matchpopulation-based cohort studyrespiratory infectionssevere acute respiratory syndrome coronavirus 2vaccine effectiveness

Substanzen

2019-nCoV Vaccine mRNA-1273BNT162 VaccineChAdOx1 nCoV-19COVID-19 Vaccines

Zitieren

APA

Lee, C. Y., Kuo, H. W., Liu, Y. L., Chuang, J. H., & Chou, J. H. (2024). Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan. Emerging Infectious Diseases, 30(3). https://doi.org/10.3201/eid3003.230893

Vancouver

Lee CY, Kuo HW, Liu YL, Chuang JH, Chou JH. Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan. Emerging Infectious Diseases. 2024;30(3). doi:10.3201/eid3003.230893

BibTeX
@article{Lee2024,
  author = {Lee, Cheng-Yi and Kuo, Hung-Wei and Liu, Yu-Lun and Chuang, Jen-Hsiang and Chou, Jih-Haw},
  title = {Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan},
  journal = {Emerging Infectious Diseases},
  year = {2024},
  volume = {30},
  number = {3},
  doi = {10.3201/eid3003.230893}
}
Kostenlos starten →